Glaukos Corporation Glaukos Corporation

Glaukos Corporation

GKOS

Rang in aandelen #2023
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Aandeelprijs
$174.03
Marktkapitalisatie
$10.26B
Verandering (1 dag)
4.34%
Verandering (1 jaar)
118.99%
Land
US
Handel Glaukos Corporation (GKOS)

Categorie

Healthcare
Aandelsplitsingen voor Glaukos Corporation (GKOS)
Het aandeel Glaukos Corporation (symbool: GKOS) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 20, 2026.
Eén aandeel GKOS dat vóór Oct 20, 2026 werd gekocht, staat nu gelijk aan 0 aandelen GKOS.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
9 x285
US
7 x127
IE
9 x162
US
2 x4
US
0 -
DE